Free shipping on all orders over $ 500

Sonepcizumab

Cat. No. M24539
Sonepcizumab Structure
Synonym:

LT 1009; Anti-Human S1P Recombinant Antibody

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Sonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).

Chemical Information
CAS Number 1031360-18-5
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Osmel Companioni, et al. Front Oncol. Targeting Sphingolipids for Cancer Therapy

[2] Sumanta K Pal, et al. Cancer. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

[3] Cornelia Volz, et al. Eur J Pharm Biopharm. Antibody therapies and their challenges in the treatment of age-related macular degeneration

[4] Zachary L Lukowski, et al. J Glaucoma. Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model

[5] Bing Xie, et al. J Cell Physiol. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization

Related S1P Receptor Products
VTX-002

VTX-002 is an orally active, selective S1P receptor 1 modulator for studies related to ulcerative colitis.

TRV045

TRV045 is an S1P receptor modulator that can be used in studies related to central nervous system disorders.

S1PR1 modulator 1 

S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC50 of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.

Ozanimod hydrochloride

Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) .

Icanbelimod

Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P1 receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis).

  Catalog
Abmole Inhibitor Catalog




Keywords: Sonepcizumab, LT 1009; Anti-Human S1P Recombinant Antibody supplier, S1P Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.